Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Slate, Fulcrum to combine in reverse merger

Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Monday 17 August →